Tag: Sobi

March 18, 2022 Off

Gamifant Approved in China for the Treatment of Primary HLH

By Dino Mustafić

Sobi has announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.

December 17, 2021 Off

EMA recommends approval for use of Kineret in COVID-19 to the European Commission

By Dino Mustafić

EMA’s human medicines committee (CHMP) has recommended extending the indication of Kineret (anakinra) to include treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPAR (soluble urokinase plasminogen activator receptor) of at least 6 ng per ml.

October 6, 2017 Off

New vice president for Sobi

By Dino Mustafić

Swedish Orphan Biovitrum AB (publ) (Sobi) has appointed Norbert Oppitz as Senior Vice President for the newly established business area Specialty Care.